

# Tushar Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967551/publications.pdf>

Version: 2024-02-01

196  
papers

24,616  
citations

11639

70  
h-index

7152

153  
g-index

202  
all docs

202  
docs citations

202  
times ranked

30686  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer. <i>Gastroenterology</i> , 2007, 133, 647-658.	0.6	2,499
2	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	1.8	1,151
3	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. <i>PLoS Biology</i> , 2012, 10, e1001450.	2.6	1,064
4	Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 30087.	5.5	1,020
5	Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell Lines. <i>Gastroenterology</i> , 2006, 130, 2113-2129.	0.6	919
6	Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. <i>Hepatology</i> , 2001, 33, 1353-1357.	3.6	915
7	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. <i>Oncogene</i> , 2011, 30, 4750-4756.	2.6	600
8	The role of proteases during apoptosis. <i>FASEB Journal</i> , 1996, 10, 587-597.	0.2	538
9	Circulating Extracellular Vesicles in Human Disease. <i>New England Journal of Medicine</i> , 2018, 379, 958-966.	13.9	515
10	Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. <i>Hepatology</i> , 2011, 54, 1237-1248.	3.6	475
11	Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012, 57, 69-76.	1.8	425
12	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
13	Worldwide trends in mortality from biliary tract malignancies. <i>BMC Cancer</i> , 2002, 2, 10.	1.1	413
14	Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. <i>FEBS Open Bio</i> , 2014, 4, 458-467.	1.0	383
15	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21098-21103.	3.3	333
16	MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. <i>Hepatology</i> , 2010, 51, NA-NA.	3.6	317
17	EVpedia: a community web portal for extracellular vesicles research. <i>Bioinformatics</i> , 2015, 31, 933-939.	1.8	317
18	A novel community driven software for functional enrichment analysis of extracellular vesicles data. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1321455.	5.5	314

#	ARTICLE	IF	CITATIONS
19	Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. <i>Journal of Hepatology</i> , 2017, 67, 603-618.	1.8	292
20	Cholangiocarcinoma—controversies and challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 189-200.	8.2	286
21	A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis. <i>Gastroenterology</i> , 2008, 135, 1953-1960.	0.6	282
22	Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular Signaling in Human Hepatocellular Cancer. <i>Genes and Cancer</i> , 2013, 4, 261-272.	0.6	277
23	Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. <i>Hepatology</i> , 2009, 50, 1152-1161.	3.6	274
24	Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. <i>Acta Neuropathologica</i> , 2013, 126, 895-905.	3.9	263
25	Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. <i>Journal of Clinical Investigation</i> , 1994, 94, 2183-2192.	3.9	259
26	Involvement of Extracellular Vesicle Long Noncoding RNA (linc-VLDLR) in Tumor Cell Responses to Chemotherapy. <i>Molecular Cancer Research</i> , 2014, 12, 1377-1387.	1.5	250
27	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. <i>Cell</i> , 2019, 177, 463-477.e15.	13.5	228
28	Cholangiocarcinoma. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 33-42.	1.7	225
29	Plasma extracellular RNA profiles in healthy and cancer patients. <i>Scientific Reports</i> , 2016, 6, 19413.	1.6	224
30	Apoptosis and hepatobiliary disease. <i>Hepatology</i> , 1995, 21, 1725-1741.	3.6	223
31	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017, 66, 1125-1143.	3.6	218
32	Modulation of hypoxia-signaling pathways by extracellular long non-coding RNA regulator of reprogramming. <i>Journal of Cell Science</i> , 2014, 127, 1585-94.	1.2	216
33	Development of an aptasensor for electrochemical detection of exosomes. <i>Methods</i> , 2016, 97, 88-93.	1.9	212
34	Interleukin-6 Contributes to Growth in Cholangiocarcinoma Cells by Aberrant Promoter Methylation and Gene Expression. <i>Cancer Research</i> , 2006, 66, 10517-10524.	0.4	209
35	Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. <i>Hepatology</i> , 1999, 30, 1128-1133.	3.6	207
36	Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 786-791.	3.3	207

#	ARTICLE	IF	CITATIONS
37	miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. <i>Cancer Research</i> , 2011, 71, 7608-7616.	0.4	206
38	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	13.9	205
39	The MicroRNA let-7a Modulates Interleukin-6-dependent STAT-3 Survival Signaling in Malignant Human Cholangiocytes. <i>Journal of Biological Chemistry</i> , 2007, 282, 8256-8264.	1.6	186
40	Long noncoding RNA in liver diseases. <i>Hepatology</i> , 2014, 60, 744-753.	3.6	178
41	Apoptosis and hepatobiliary disease*1. <i>Hepatology</i> , 1995, 21, 1725-1741.	3.6	177
42	Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. , 2016, 161, 67-78.		177
43	Large Differences in Small RNA Composition Between Human Biofluids. <i>Cell Reports</i> , 2018, 25, 1346-1358.	2.9	163
44	Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. <i>Hepatology</i> , 1997, 25, 958-963.	3.6	159
45	Extracellular Vesicles from Bone Marrow-Derived Mesenchymal Stem Cells Improve Survival from Lethal Hepatic Failure in Mice. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1262-1272.	1.6	159
46	Dysregulation of Apoptosis as a Mechanism of Liver Disease: An Overview. <i>Seminars in Liver Disease</i> , 1998, 18, 105-114.	1.8	158
47	Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. <i>BMC Gastroenterology</i> , 2002, 2, 2.	0.8	157
48	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	13.5	152
49	Transforming growth factor- $\beta$ 2 inhibition of proteasomal activity: a potential mechanism of growth arrest. <i>American Journal of Physiology - Cell Physiology</i> , 2003, 285, C277-C285.	2.1	129
50	Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. <i>Journal of Hepatology</i> , 2006, 44, 1055-1065.	1.8	121
51	Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. <i>Hepatology</i> , 1999, 29, 1037-1043.	3.6	117
52	Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 24900.	5.5	117
53	Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes. <i>Clinical Cancer Research</i> , 2010, 16, 957-966.	3.2	108
54	The Role of MicroRNAs in Human Liver Cancers. <i>Seminars in Oncology</i> , 2011, 38, 752-763.	0.8	106

#	ARTICLE	IF	CITATIONS
55	Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2014, 34, 456-464.	1.8	106
56	The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. <i>Journal of Gastroenterology</i> , 2019, 54, 763-773.	2.3	103
57	Extracellular vesicles from bone marrow-derived mesenchymal stem cells protect against murine hepatic ischemia/reperfusion injury. <i>Liver Transplantation</i> , 2017, 23, 791-803.	1.3	99
58	Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1123-1128.	2.4	96
59	Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. <i>Liver International</i> , 2006, 26, 1047-1053.	1.9	93
60	Endoscopic Ultrasound Versus CT Scan for Detection of the Metastases to the Liver. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 367-373.	1.1	93
61	Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120-catenin activity. <i>Nature Cell Biology</i> , 2015, 17, 1145-1157.	4.6	93
62	Microfluidic compartments with sensing microbeads for dynamic monitoring of cytokine and exosome release from single cells. <i>Analyst</i> , 2016, 141, 679-688.	1.7	90
63	Surgery in the Patient With Liver Disease. <i>Mayo Clinic Proceedings</i> , 1999, 74, 593-599.	1.4	89
64	Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer. <i>Briefings in Functional Genomics</i> , 2016, 15, 249-256.	1.3	86
65	Î³-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP-Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway. <i>Cancer Research</i> , 2005, 65, 11437-11446.	0.4	85
66	Silymarin in the Treatment of Patients With Primary Biliary Cirrhosis With a Suboptimal Response to Ursodeoxycholic Acid. <i>Hepatology</i> , 2000, 32, 897-900.	3.6	80
67	Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. <i>Cancer Science</i> , 2020, 111, 98-111.	1.7	79
68	Preoperative evaluation of patients with liver disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 266-276.	1.7	78
69	Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. <i>Journal of Hepatology</i> , 2007, 46, 222-229.	1.8	75
70	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. <i>Gut</i> , 2017, 66, 1268-1277.	6.1	75
71	Comparison of miRNA quantitation by Nanostring in serum and plasma samples. <i>PLoS ONE</i> , 2017, 12, e0189165.	1.1	74
72	MicroRNA expression profiling: A molecular tool for defining the phenotype of hepatocellular tumors. <i>Hepatology</i> , 2008, 47, 1807-1809.	3.6	73

#	ARTICLE	IF	CITATIONS
73	Extracellular RNAs: development as biomarkers of human disease. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27495.	5.5	72
74	Liver transplantation for intrahepatic cholangiocarcinoma. <i>Liver Transplantation</i> , 2018, 24, 634-644.	1.3	71
75	Advances in the diagnosis, evaluation and management of cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 294-299.	1.0	67
76	Clozapine and the mitogen-activated protein kinase signal transduction pathway: Implications for antipsychotic actions. <i>Biological Psychiatry</i> , 2005, 57, 617-623.	0.7	65
77	BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma. <i>Molecular Cancer</i> , 2017, 16, 22.	7.9	64
78	Inhibition of Bile-Salt-Induced Hepatocyte Apoptosis by the Antioxidant Lazaroid U83836E. <i>Toxicology and Applied Pharmacology</i> , 1997, 142, 116-122.	1.3	62
79	IL-6 activates serum and glucocorticoid kinase via p38 $\beta$ mitogen-activated protein kinase pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 289, C971-C981.	2.1	61
80	Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. <i>Hepatology</i> , 2001, 33, 43-51.	3.6	60
81	Cholangiocarcinoma: emerging approaches to a challenging cancer. <i>Current Opinion in Gastroenterology</i> , 2007, 23, 317-323.	1.0	60
82	Noncoding RNA as Therapeutic Targets for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2015, 35, 063-074.	1.8	60
83	GAIP Interacting Protein C-Terminus Regulates Autophagy and Exosome Biogenesis of Pancreatic Cancer through Metabolic Pathways. <i>PLoS ONE</i> , 2014, 9, e114409.	1.1	59
84	Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. <i>Theranostics</i> , 2019, 9, 7239-7250.	4.6	59
85	Cholangiocarcinoma: New Insights into Disease Pathogenesis and Biology. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 871-884.	1.9	58
86	Translational Regulation of X-Linked Inhibitor of Apoptosis Protein by Interleukin-6. <i>Cancer Research</i> , 2004, 64, 1293-1298.	0.4	57
87	Targeting of the Akt-Nuclear Factor- $\kappa$ B Signaling Network by [1-(4-Chloro-3-nitrobenzenesulfonyl)-1 <i>H</i> -indol-3-yl]-methanol (OSU-A9), a Novel Indole-3-Carbinol Derivative, in a Mouse Model of Hepatocellular Carcinoma. <i>Molecular Pharmacology</i> , 2009, 76, 957-968.	1.0	57
88	Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. <i>Hepatology</i> , 2002, 36, 641-651.	3.6	55
89	Inhibition of cholangiocarcinoma growth by Tannic acid. <i>Hepatology</i> , 2003, 37, 1097-1104.	3.6	54
90	Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer. <i>PLoS ONE</i> , 2013, 8, e76136.	1.1	54

#	ARTICLE	IF	CITATIONS
91	Increased susceptibility of cholangiocytes to tumor necrosis factor- $\alpha$ cytotoxicity after bile duct ligation. American Journal of Physiology - Cell Physiology, 2003, 285, C183-C194.	2.1	52
92	Extracellular vesicles in liver diseases. American Journal of Physiology - Renal Physiology, 2017, 312, G194-G200.	1.6	52
93	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. Journal of Extracellular Vesicles, 2015, 4, 26533.	5.5	51
94	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. Journal of Hematology and Oncology, 2008, 1, 18.	6.9	50
95	Hepatic miR-29ab1 expression modulates chronic hepatic injury. Journal of Cellular and Molecular Medicine, 2012, 16, 2647-2654.	1.6	50
96	New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. Journal of Gastroenterology, 2014, 49, 165-172.	2.3	50
97	Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Annals of Hepatology, 2018, 17, 604-614.	0.6	50
98	Brain Tumor Enhancement in Magnetic Resonance Imaging. Investigative Radiology, 2005, 40, 792-797.	3.5	48
99	Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. American Journal of Physiology - Renal Physiology, 2003, 284, G837-G852.	1.6	46
100	Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sciences, 2006, 78, 2494-2502.	2.0	46
101	microRNAs in liver disease: From diagnostics to therapeutics. Clinical Biochemistry, 2013, 46, 946-952.	0.8	45
102	Preexisting atrial fibrillation and cardiac complications after liver transplantation. Liver Transplantation, 2015, 21, 314-320.	1.3	43
103	Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. Hepatology, 1999, 30, 811-815.	3.6	42
104	The Efficacy of Gadobenate Dimeglumine (Gd-BOPTA) at 3 Tesla in Brain Magnetic Resonance Imaging. Investigative Radiology, 2006, 41, 244-248.	3.5	42
105	Epigallocatechin gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver International, 2009, 29, 670-677.	1.9	42
106	Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer. Hepatology Communications, 2020, 4, 298-313.	2.0	42
107	<i>In vitro</i> toxicology studies of extracellular vesicles. Journal of Applied Toxicology, 2017, 37, 310-318.	1.4	41
108	Use of a Hollow Fiber Bioreactor to Collect Extracellular Vesicles from Cells in Culture. Methods in Molecular Biology, 2018, 1740, 35-41.	0.4	40

#	ARTICLE	IF	CITATIONS
109	APOPTOSIS IN HEPATIC PATHOPHYSIOLOGY. <i>Clinics in Liver Disease</i> , 2000, 4, 295-317.	1.0	39
110	Current approaches to the diagnosis and treatment of cholangiocarcinoma. <i>Current Gastroenterology Reports</i> , 2006, 8, 30-37.	1.1	39
111	TIMP-1 Attenuates Bloodâ€Brain Barrier Permeability in Mice with Acute Liver Failure. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1041-1049.	2.4	38
112	Analysis of Extracellular RNA by Digital PCR. <i>Frontiers in Oncology</i> , 2014, 4, 129.	1.3	38
113	Extracellular Vesicleâ€Based Therapeutic Targeting of $\beta$ -Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. <i>Hepatology Communications</i> , 2019, 3, 525-541.	2.0	38
114	Biomechanical evaluation of the New Zealand white rabbit lumbar spine: a physiologic characterization. <i>European Spine Journal</i> , 2000, 9, 250-255.	1.0	36
115	Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. <i>Hepatology</i> , 2003, 38, 158-166.	3.6	34
116	Molecular diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 114-123.	1.4	34
117	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2021, 74, 2622-2632.	3.6	31
118	Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. <i>Gastroenterology</i> , 2004, 127, 1787-1797.	0.6	30
119	Candidate therapeutic agents for hepatocellular cancer can be identified from phenotypeâ€associated gene expression signatures. <i>Cancer</i> , 2009, 115, 3738-3748.	2.0	29
120	Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma. <i>PLoS ONE</i> , 2010, 5, e15195.	1.1	29
121	Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. <i>Annals of Hepatology</i> , 2018, 17, 274-285.	0.6	29
122	Identifying opportunities for improved colorectal cancer screening in primary care. <i>Preventive Medicine</i> , 2004, 39, 239-246.	1.6	27
123	Apoptosis in liver transplantation: A mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease. <i>Liver Transplantation</i> , 1998, 4, 42-50.	1.9	26
124	Chemotherapeutic stress selectively activates NF- $\kappa$ B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 293, C749-C760.	2.1	26
125	Non-coding RNAs as therapeutic targets in hepatocellular cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 1073-80.	0.8	26
126	Prevalence, Risk Factors, and Survival of Patients with Intrahepatic Cholangiocarcinoma. <i>Annals of Hepatology</i> , 2017, 16, 565-568.	0.6	25



#	ARTICLE	IF	CITATIONS
127	Extending gene ontology in the context of extracellular RNA and vesicle communication. Journal of Biomedical Semantics, 2016, 7, 19.	0.9	24
128	Emerging Insights Into the Role of MicroRNAs in the Pathogenesis of Cholangiocarcinoma. Gene Expression, 2014, 16, 93-99.	0.5	23
129	Safety of bovine milk derived extracellular vesicles used for delivery of RNA therapeutics in zebrafish and mice. Journal of Applied Toxicology, 2020, 40, 706-718.	1.4	23
130	Nanovesicle-mediated delivery of anticancer agents effectively induced cell death and regressed intrahepatic tumors in athymic mice. Laboratory Investigation, 2018, 98, 895-910.	1.7	22
131	Milk-derived Extracellular Vesicles for Therapeutic Delivery of Small Interfering RNAs. Methods in Molecular Biology, 2018, 1740, 187-197.	0.4	21
132	Liver Transplantation in Patients With Atrial Fibrillation. Transplantation Proceedings, 2013, 45, 2302-2306.	0.3	18
133	Isolation of Extracellular Nanovesicle MicroRNA from Liver Cancer Cells in Culture. Methods in Molecular Biology, 2013, 1024, 11-18.	0.4	18
134	Reversible non-ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single-centre experience. Liver International, 2014, 34, e105-10.	1.9	17
135	Extracellular vesicle noncoding RNA: New players in the diagnosis and pathogenesis of cholangiocarcinoma. Hepatology, 2014, 60, 782-784.	3.6	17
136	Tannic Acid Inhibits Cholangiocyte Proliferation after Bile Duct Ligation via a Cyclic Adenosine 5'-Monophosphate-Dependent Pathway. American Journal of Pathology, 2005, 166, 1671-1679.	1.9	16
137	Preneoplastic conditions underlying bile duct cancer. Langenbeck's Archives of Surgery, 2012, 397, 861-867.	0.8	16
138	Role of Plasmapheresis in Thrombocytopenic Purpura Associated With Waldenström's Macroglobulinemia. Mayo Clinic Proceedings, 1996, 71, 597-600.	1.4	15
139	Double-stranded RNA activates a p38 MAPK-dependent cell survival program in biliary epithelia. American Journal of Physiology - Renal Physiology, 2003, 284, G924-G932.	1.6	14
140	One-carbon metabolism-related micronutrients intake and risk for hepatocellular carcinoma: A prospective cohort study. International Journal of Cancer, 2020, 147, 2075-2090.	2.3	14
141	A Fluorometric Assay for Quantitating DNA Strand Breaks during Apoptosis. Analytical Biochemistry, 1995, 229, 229-235.	1.1	13
142	Immune escape in hepatocellular cancer: Is a good offense the best defense?. Hepatology, 1999, 30, 576-578.	3.6	13
143	Screening for Colorectal Cancer in Elderly Persons. Journal of Aging and Health, 2008, 20, 126-139.	0.9	13
144	Circulating Extracellular RNA Markers of Liver Regeneration. PLoS ONE, 2016, 11, e0155888.	1.1	13

#	ARTICLE	IF	CITATIONS
145	Functional Modulation of Gene Expression by Ultraconserved Long Non-coding RNA TUC338 during Growth of Human Hepatocellular Carcinoma. <i>IScience</i> , 2018, 2, 210-220.	1.9	12
146	Isolation of Tissue Extracellular Vesicles from the Liver. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	12
147	Educational Intervention in Primary Care Residentsâ€™ Knowledge and Performance of Hepatitis B Vaccination in Patients with Diabetes Mellitus. <i>Southern Medical Journal</i> , 2015, 108, 510-515.	0.3	12
148	MicroRNAs as paracrine signaling mediators in cancers and metabolic diseases. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 577-590.	2.2	11
149	Biochemical Safety of Ablative Yttrium-90 Radioembolization for Hepatocellular Carcinoma as a Function of Percent Liver Treated. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 861-870.	1.8	11
150	Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive HCC Resulting in Complete Pathologic Response. <i>Hepatology</i> , 2021, 74, 525-527.	3.6	10
151	Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2624-2634.	3.3	10
152	Biological Nanotherapeutics for Liver Disease. <i>Hepatology</i> , 2021, 74, 2863-2875.	3.6	10
153	Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2022, 6, 120-125.	1.2	10
154	Dysfunctional EGFR and oxidative stress-induced PKD1 signaling drive formation of DCLK1+ pancreatic stem cells. <i>IScience</i> , 2021, 24, 102019.	1.9	9
155	Tunneling Nanotube-Mediated Communication: A Mechanism of Intercellular Nucleic Acid Transfer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5487.	1.8	9
156	Pifithrin-Î± Enhances Chemosensitivity by a p38 Mitogen-Activated Protein Kinase-Dependent Modulation of the Eukaryotic Initiation Factor 4E in Malignant Cholangiocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 1153-1161.	1.3	8
157	Assessment of response to therapy in hepatocellular carcinoma. <i>Annals of Medicine</i> , 2014, 46, 130-137.	1.5	8
158	Multiplexed Detection and Quantitation of Extracellular Vesicle RNA Expression Using NanoString. <i>Methods in Molecular Biology</i> , 2018, 1740, 177-185.	0.4	8
159	Fabrication and Characterization of a Biomaterial Based on Extracellular-Vesicle Functionalized Graphene Oxide. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 686510.	2.0	8
160	Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. <i>Digestive and Liver Disease</i> , 2022, 54, 964-972.	0.4	8
161	Development of a Lyophilized Off-the-Shelf Mesenchymal Stem Cell-Derived Acellular Therapeutic. <i>Pharmaceutics</i> , 2022, 14, 849.	2.0	8
162	Molecular Evolution of Genetic Susceptibility to Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2014, 59, 986-991.	1.1	7

#	ARTICLE	IF	CITATIONS
163	Isolation of Extracellular RNA from Bile. <i>Methods in Molecular Biology</i> , 2018, 1740, 59-67.	0.4	7
164	Radioembolization for hepatocellular carcinoma: The time has come. <i>Hepatology</i> , 2018, 67, 820-822.	3.6	7
165	Aberrant local renin-angiotensin II responses in the pathogenesis of primary sclerosing cholangitis. <i>Medical Hypotheses</i> , 2003, 61, 64-67.	0.8	6
166	A Single-Institute Experience with Sorafenib in Untreated and Previously Treated Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2010, 78, 210-212.	0.9	6
167	Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma. <i>Annals of Hepatology</i> , 2018, 17, 969-979.	0.6	6
168	Early Detection of Hepatocellular Carcinoma: Expanding the Utility of Circulating Tumor Markers. <i>Hepatology</i> , 2019, 69, 1855-1857.	3.6	6
169	Non-Coding RNAs as Therapeutic Targets in Hepatocellular Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 1073-1080.	0.8	5
170	Network analyses-based identification of circular ribonucleic acid-related pathways in intrahepatic cholangiocarcinoma. <i>Tumor Biology</i> , 2018, 40, 101042831879576.	0.8	5
171	Therapeutic Efficacy of Vitamin D in Experimental c-MET <sup>2</sup> -Catenin-Driven Hepatocellular Cancer. <i>Gene Expression</i> , 2019, 19, 151-159.	0.5	5
172	Real versus simulated galactic cosmic radiation for investigating cancer risk in the hematopoietic system - are we comparing apples to apples?. <i>Life Sciences in Space Research</i> , 2021, 29, 8-14.	1.2	5
173	Machine learning analysis of volatolomic profiles in breath can identify non-invasive biomarkers of liver disease: A pilot study. <i>PLoS ONE</i> , 2021, 16, e0260098.	1.1	5
174	Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 804-810.	1.1	5
175	Droplet Digital PCR for Quantitation of Extracellular RNA. <i>Methods in Molecular Biology</i> , 2018, 1740, 155-162.	0.4	4
176	Long non-coding RNA regulation of liver cancer stem cell self-renewal offers new therapeutic targeting opportunities. <i>Stem Cell Investigation</i> , 2016, 3, 1.	1.3	4
177	Impact of Age on Screening and Surveillance for Primary Liver Cancer. <i>American Journal of Gastroenterology</i> , 2006, 101, 768-774.	0.2	3
178	Clinical diagnosis and management of intrahepatic cholangiocarcinoma. <i>Clinical Liver Disease</i> , 2014, 3, 56-59.	1.0	3
179	Mesenchymal stem cell derived extracellular vesicles: a promising new therapeutic approach for hepatic injury. <i>Biotarget</i> , 2017, 1, 12-12.	0.5	3
180	Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C. <i>Cancer Prevention Research</i> , 2019, 12, 891-902.	0.7	3

#	ARTICLE	IF	CITATIONS
181	Increasing mortality of intrahepatic cholangiocarcinoma in the US: are gender-specific risk factors important?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 635-636.	0.7	3
182	Aspirin and Statin Use and the Risk of Gallbladder Cancer. <i>Cancers</i> , 2021, 13, 1186.	1.7	3
183	Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth. <i>FEBS Open Bio</i> , 2021, 11, 3276-3292.	1.0	2
184	What are the key challenges in the pharmacological management of cholangiocarcinoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 531-533.	0.9	2
185	Resting Thallium-201 Scintigraphy for Identifying Viable Myocardium in a Patient With Severe Left Ventricular Dysfunction. <i>Mayo Clinic Proceedings</i> , 1993, 68, 63-67.	1.4	1
186	P38 mitogen activated protein kinase (MAPK) modulates chemosensitivity of malignant cholangiocytes. <i>Gastroenterology</i> , 2000, 118, A1017.	0.6	1
187	Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. <i>Seminars in Interventional Radiology</i> , 2019, 36, 287-297.	0.3	1
188	Authors' response to "How to dispel myths in the treatment of hepatic encephalopathy?". <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, E2-E2.	1.7	1
189	Silymarin for patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. <i>Gastroenterology</i> , 2000, 118, A901.	0.6	0
190	Corrigendum to: "Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma" [Hepatology 2012;57:69-76]. <i>Journal of Hepatology</i> , 2012, 57, 1160.	1.8	0
191	Transcribed ultraconserved regions are aberrantly expressed and can be modulated by interleukin 6 in cholangiocarcinoma. <i>Lancet, The</i> , 2013, 381, S26.	6.3	0
192	Detection of Circulating RNA Using Nanopore Sequencing. <i>Methods in Molecular Biology</i> , 2021, 2348, 273-284.	0.4	0
193	Evaluation of In Vivo Toxicity of Biological Nanoparticles. <i>Current Protocols</i> , 2021, 1, e249.	1.3	0
194	Quantitation of Long Noncoding RNA Using Digital PCR. <i>Methods in Molecular Biology</i> , 2021, 2348, 113-121.	0.4	0
195	Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma. <i>Annals of Hepatology</i> , 2018, 17, 0-10.	0.6	0
196	Hepatocellular Carcinoma Risk Prediction in the NIH-AARP Diet and Health Study Cohort: A Machine Learning Approach. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 69-81.	1.8	0